Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.
about
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndromeImaging brain mechanisms in chronic visceral pain.Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes? The Con Argument.Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humansThe Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting.Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.Review article: new receptor targets for medical therapy in irritable bowel syndromeSerotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients.Management of functional abdominal pain and irritable bowel syndrome in children and adolescents.Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotoninEvidence-based clinical practice guidelines for irritable bowel syndrome.Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical studyClinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndromeThe brain-gut axis in abdominal pain syndromes.Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.Rifaximin for the treatment of irritable bowel syndrome.Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.Colectomy for constipation: time trends and impact based on the US Nationwide Inpatient Sample, 1998-2011.The hormone ghrelin prevents traumatic brain injury induced intestinal dysfunction.Interplay between inflammation, immune system and neuronal pathways: effect on gastrointestinal motility.Medical Therapies in the Pipeline for Irritable Bowel Syndrome.Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome?The search for biomarkers and endophenotypes in functional gastrointestinal disorders.The utilisation and diagnostic yield of radiological imaging in a specialist functional GI disorder clinic: an 11-year retrospective study.The rising tide of cholecystectomy for biliary dyskinesia.Emotional awareness and expression training improves irritable bowel syndrome: A randomized controlled trial.Hysterical again: the gastrointestinal woman in medical discourse.
P2860
Q26860280-107A378B-345A-4290-8AE1-4DD61DAE2D64Q28087191-7BEA9CD9-CB78-4B27-9D32-0AD63455F3F4Q33653697-C461B50C-DD48-4B00-9A68-B3600B8409F5Q33665390-7D9BD758-C0E6-440F-BD61-929701236E0AQ33688135-B6CC300B-AD28-43A8-8A33-01291C2A83C8Q33780866-374345FD-3328-4F33-8199-8A3929853321Q33959307-87D60599-B35D-4EAC-88E9-67399D12257DQ33987389-193B25D6-21C6-4142-83D9-5A6C708D4528Q33995802-770C4CD5-286C-4FE6-B5F2-1F73E28458D7Q34309302-0E9EFB22-12E3-4DD1-9F29-574EAD29C9DEQ34409219-8FC6FD42-077B-41C0-9B09-E26D0FF4AD6BQ34790812-19270C7F-FA02-4875-B136-21351C9127EEQ35513973-9E06B367-3E3F-4FB2-A4C4-6D693CAF5716Q35929170-95B02DA1-25C1-40B7-8FD7-D886D7B9D78CQ35938424-F01870D5-CF74-454E-B0D6-8A02D2CFAD9EQ36166972-D072702A-0F90-4F9E-87CC-385AD5C3DA45Q36309936-DE96733B-5322-474B-A7BA-8D775956D303Q37280260-2A44AEBF-4298-454C-88B1-5D396A90BB78Q37973803-D672DF77-2B34-4A02-B7FB-3BA26939DBCBQ37976477-899B3148-97AD-4A97-9D56-7178BDC16DDCQ39885291-DDD923F1-DA13-44F5-AF11-8E4108B54E34Q40481243-7E3410A6-8A5B-442C-9506-BE71604B3E46Q41913798-08C5052E-5F97-466B-B4ED-D23DF3D1815DQ42342939-DB3C4F98-0654-4EB4-9FB2-4C68B4104A61Q42374437-87949E9F-DBB4-43E5-AE3F-1524A0D04AA2Q42738877-56A2062C-C246-4BCD-915B-BB0A7D197EFFQ42870005-244D193A-C006-4C27-8C97-F17F032137E9Q44734975-8B005BB3-73FD-4684-B9AC-1E7FBC4DAB1BQ46119112-7C3C0CEA-EB15-4A46-9B32-E6ECAA9BA085Q47686007-AB630232-A7E8-4833-B378-BBC537F0EFDEQ48349048-66819B19-DA80-44E0-9E74-FA10A0DB5AD5
P2860
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Challenges to the therapeutic ...... points and regulatory hurdles.
@en
Challenges to the therapeutic ...... points and regulatory hurdles.
@nl
type
label
Challenges to the therapeutic ...... points and regulatory hurdles.
@en
Challenges to the therapeutic ...... points and regulatory hurdles.
@nl
prefLabel
Challenges to the therapeutic ...... points and regulatory hurdles.
@en
Challenges to the therapeutic ...... points and regulatory hurdles.
@nl
P2860
P1433
P1476
Challenges to the therapeutic ...... points and regulatory hurdles.
@en
P2093
P2860
P304
P356
10.1053/J.GASTRO.2008.09.005
P407
P577
2008-10-09T00:00:00Z